OXB Solutions' first manufacturing facility

Leaders in gene and cell therapy

Oxford BioMedica acquired a manufacturing facility from RecipharmCobra Biologics, the specialist biologics division of Recipharm AB. The manufacturing facility will enable Oxford BioMedica to have greater control of the production of its proprietary LentiVector® gene delivery technology in order to support five of the Company’s clinical programmes.  With the ocular products partnered with sanofi-aventis advancing into Phase I/II development during 2011, in addition to the planned progression of ProSavin® into a randomised Phase II study for Parkinson’s disease in 2012, the facility is expected to deliver long-term operational and financial efficiencies for the Company in comparison to outsourcing processes to a specialist contract manufacturing organisation.  This acquisition will also reduce the Company’s dependence on a single manufacturing source for its growing clinical portfolio and facilitate the rapid implementation of improved manufacturing processes at increased scale.

The facility totals approximately 16,000 square feet, which includes c. 4,400 square feet in cleanrooms, and is already configured to meet the Company’s manufacturing requirements.  The facility was previously approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to Good Manufacturing Practice (GMP) standards.  Oxford BioMedica anticipates a minimum of 12 months to re-commission the facility which will include the first phase of staff recruitment towards the anticipated fully-operational level of about 35 to 40 staff.  The Company estimates an annual running cost of approximately £2.2 million per annum for the facility.

Our illustration forms part of communications materials, including a new website, that will showcase the new facilities to investors and other important stakeholders such as the UK Government.

investor communication materials / photography and illustration